Francisco J. Esteva on the DESTINY-Breast06 trial
Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared a post on LinkedIn:
“One of the most anticipated presentations at the 2024 Annual Meeting of ASCO is the DESTINY-Breast06 trial. In this study, 866 patients with HER2-Low, hormone receptor-positive metastatic breast cancer, who had progressed within 6 months of endocrine therapy plus a CDK4/6 inhibitor or after two lines of endocrine therapy in the metastatic setting, were randomized to receive trastuzumab deruxtecan (Enhertu) or chemotherapy of the physician’s choice.
According to a press release from one of the sponsors, the trial met its primary endpoint. Progression-free survival was longer in the Enhertu group, both for the HER2-Low group (primary endpoint) and the overall group, which included 153 patients with HER2 Ultra Low metastatic breast cancer.
In this video, I provide the necessary context and background to understand these preliminary results and discuss how we might integrate these data into clinical practice in the future. A major implication of this trial is the potential change in HER2 testing methods and interpretation. Should we test all tumors for HER2? What treatments are best for each patient, and in what sequence?
The DESTINY-B06 trial may indeed change clinical practice. However, we should step back and reflect on the upcoming paradigm shifts regarding HER2 testing and targeted therapy for this evolving target.”
Source: Francisco J. Esteva/LinkedIn